Skip to Content
Course

Preclinical Drug Discovery Immersive

BIOL-40408

Learn about Preclinical Drug Discovery 

This 5-day immersive course provides an in-depth examination of the essential elements involved in developing new therapeutic drugs. Emphasizing preclinical discovery and development, the curriculum covers the critical requirements for progressing a program to clinical entry. Students will analyze strategies for identifying optimal drug targets and selecting key molecules that effectively modulate these targets. The course addresses fundamental aspects of pharmacology and drug safety, as well as the preparation necessary for Investigational New Drug (IND) and regulatory submissions. Additionally, students will explore career paths within biotechnology and pharmaceutical industries, gain insight into portfolio management, and evaluate strategic business considerations related to program advancement or discontinuation.

 

Key Themes

 
  1. Target Identification and Validation
  2. Hit Discovery and Lead Identification
  3. Preclinical Pharmacology and Safety Assessment
  4. IND, Regulatory and Clinical Strategy, and Business Case
  5. Future Trends, Career Opportunities, and Class Simulation

Learning Objectives

 

By the end of this course, students will be able to: 

  • Understand the stages and processes intrinsic to drug discovery and the progression from target discovery through successful approval to initiate clinical studies.
  • Recognize fundamental elements required for identifying and validating appropriate targets, integrating emerging technologies such as AI, and incorporating modalities and next generation approaches to address challenging disease biology.
  • Demonstrate familiarity with early screening workflows, from identifying target hits to chemistry and antibody engineering, as well as conducting early biology, metabolism, and safety assessments to profile lead candidates.
  • Describe the advancement of molecules through preclinical phases, encompassing in vitro and in vivo pharmacology, disease modeling (in vivo and ex vivo), and toxicological and safety evaluations.
  • Articulate the components involved in Regulatory submissions as programs prepare for clinical transition.
  • Evaluate portfolio management strategies and business considerations for continuing or discontinuing preclinical programs.
  • Review and discuss diverse career paths within Industry, including how to leverage relevant experiences for both preclinical and clinical positions.

Prerequisites

 

There are no required prerequisites for this course. Students are encouraged to have a foundational understanding of biology, chemistry, pharmacology, or related life sciences prior to enrollment. Familiarity with basic concepts in life sciences will support successful engagement with the material. Professional or academic experience in biotechnology, pharmaceuticals, or healthcare is helpful but not required.

 

Format

 

The Preclinical Drug Discovery Immersive Course comprises five full days of in-person instruction on the UC San Diego campus. Each day will focus on a specific theme relevant to preclinical drug discovery. Each day will consist of four modules, each lasting 1.5–2 hours and focusing on core topics for the themes. Lunch and two breaks are scheduled. The final day features a team simulation combining concepts of drug discovery, roles, timelines, and responses to real-world challenges, emphasizing communication and problem-solving.

All enrolled students will receive access to the course material online, through Canvas, on the start date. 

Course Information

Hybrid
3.00 units
$3,200.00

Course sessions

Add To Cart

Section ID:

199264

Class type:

In-class + web based.

This learning experience is intentionally designed as a combination of in-class and web-based instruction. In-class meetings follow the published schedule. Students are also expected to engage with course content online during the published course dates.

Textbooks:

No textbook required.

Policies:

  • No refunds after: 9/14/2026

Schedule:

Date Day Start End Location
9/14/2026 Mon 8:00 a.m. 5:00 p.m. Room 555, UCSD Division of Extended Studies 8980, 8980 Villa La Jolla Drive, San Diego
9/15/2026 Tue 8:00 a.m. 5:00 p.m. Room 555, UCSD Division of Extended Studies 8980, 8980 Villa La Jolla Drive, San Diego
9/16/2026 Wed 8:00 a.m. 5:00 p.m. Room 555, UCSD Division of Extended Studies 8980, 8980 Villa La Jolla Drive, San Diego
9/17/2026 Thu 8:00 a.m. 5:00 p.m. Room 555, UCSD Division of Extended Studies 8980, 8980 Villa La Jolla Drive, San Diego
9/18/2026 Fri 8:00 a.m. 5:00 p.m. Room 555, UCSD Division of Extended Studies 8980, 8980 Villa La Jolla Drive, San Diego
Add To Cart

Instructor: Kristen Taylor Meadows, Ph.D.

Kristen Taylor Meadows, Ph.D.
Kristen Taylor Meadows, Ph.D., is an Immunologist with over 15 years of experience in drug discovery and development, with a focus on autoimmune and inflammatory diseases. She has worked across the biotech and pharmaceutical landscape, from early-stage startups to global pharma, bringing scientific leadership and strategic insight to programs from target validation through clinical development.

Dr. Taylor Meadows was part of the team that advanced ozanimod (Zeposia®) to FDA approval for Multiple Sclerosis and Ulcerative Colitis. Her work contributed to the understanding of its mechanism of action, differentiation, biomarker development, and indication expansion. In total, she has contributed to eight IND submissions and one NDA and supported multiple clinical-stage programs including a Phase III asset for Pulmonary Arterial Hypertension and Phase II programs in Crohn’s Disease, Ulcerative Colitis, and Asthma.

She has held senior leadership roles including Vice President of Discovery and Translational Science at Endpoint Health and Senior Director of Biology at Gossamer Bio, where she led the In Vivo Pharmacology Team that supported preclinical and clinical assets. Her areas of expertise include vitro assay development, in vivo pharmacology, translational science, and biomarker strategy.

Dr. Taylor Meadows is currently the Founder and Principal Consultant of KRTM Consulting Services, LLC, where she advises small and mid-sized biotech companies on discovery and early development strategy, including experimental design, platform development, and scientific positioning.

She holds a B.S. in Biochemistry from the University of Arizona, a Ph.D. in Biomedical Sciences from UC San Diego, and completed her postdoctoral training in Immunology at The Scripps Research Institute. Dr. Taylor Meadows is an active contributor to the scientific community through publications and conference presentations.

 
Full Bio

FAQs

Sheraton La Jolla
  • Go to:  www.sheratonlajolla.com
  • Enter desired stay dates
  • Go to special rate drop down arrow
  • Go to Corporate/Promo code and type in:  UC0 (zero, not ‘O’) (subject to availability)
Residence Inn by Marriott San Diego La Jolla Estancia La Jolla  Hyatt Regency La Jolla  Embassy Suites by Hilton San Diego La Jolla 
  • Go to: https://www.hilton.com/en/hotels/sanljes-embassy-suites-san-diego-la-jolla/
  • Call Reservations at 858-453-0400 to ask for UC San Diego rate (subject to availability)

Yes, the Preclinical Drug Discovery Immersive course (3.0 units) may be used as a substitute for either the Essentials of Drug Discovery and Development course (3.0 units) or the Present & Future of Drug Discovery and Development course (3.0 units) in the Drug Discovery and Development Certificate